PGNY (Progyny) Moat Score: 5/10 (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PGNY Progyny Inc PGNY
94 GF Score
Price $25.88
GF Value $28.66
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Progyny Moat Score?

Progyny PGNY +1.87% 94 Moat Score is 5 as of Aug. 14, 2026. GuruFocus rates PGNY with a GF Score™ of 94/100 and a GF Value™ of $28.66 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 18 Healthcare Plans companies, Progyny ranks better than 55.56% on this metric.

Progyny has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Progyny has Narrow Moat: Progyny Inc has a solid narrow moat due to its specialized fertility benefits management services and strong client relationships. While it has a unique service offering, the competitive landscape and potential for new entrants limit its moat to a narrow classification.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Progyny might have Narrow Moat - Solid narrow moat.

Progyny  (NAS:PGNY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Progyny Moat Score Related Terms

PGNY vs CLOV, ALHC, PFHO: Moat Score Comparison

For the Healthcare Plans subindustry, Progyny's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Progyny Moat Score vs Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, Progyny's Moat Score distribution charts can be found below:

* The bar in red indicates where Progyny's Moat Score falls into.


PGNY
94GF Score
Progyny Inc PGNY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Progyny (PGNY) has a Moat Score of 5 as of Aug. 14, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Progyny ranks #8 out of 18 companies in the Healthcare Plans industry, placing it in the top 44.4%.
Is Progyny's Moat Score too high?
Progyny's current Moat Score is 5. The Healthcare Plans industry median Moat Score is 4.00. Progyny's value of 5 is 25% above this industry median. Based on the distribution chart, Progyny ranks #8 out of 18 companies in the Healthcare Plans industry, which is above the industry midpoint. Overall, Progyny has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Progyny's Moat Score compare to CLOV and ALHC?
According to the Healthcare Plans industry distribution chart, Progyny ranks #8 out of 18 companies for Moat Score. This puts Progyny in the upper half of its industry. The industry median Moat Score is 4.00. Progyny's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Plans company?
The median Moat Score among Healthcare Plans companies is 4.00, based on 18 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Progyny's current Moat Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Healthcare Plans industry, the median Moat Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Progyny's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Progyny stock overvalued right now?
Based on GuruFocus' analysis, Progyny (PGNY) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.66, compared to a current price of $25.88 — trading 9.7% below its estimated fair value. The current Moat Score is 5 and 25% above the Healthcare Plans industry median of 4.00. Progyny's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Progyny (PGNY), the current Moat Score is 5 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Progyny (PGNY) Overvalued in 2026?

Based on GuruFocus' analysis, Progyny stock appears to be undervalued. The current stock price of $25.88 is trading 9.7% below its estimated GF Value™ of $28.66. GuruFocus considers Progyny to be Modestly Undervalued.

Key valuation signals for PGNY:

  • Moat Score: 5
  • GF Value™: $28.66 vs. price of $25.88 (9.7% below fair value)
  • GF Score™: 94/100 with 2 warning signs
  • Industry Position: 25% above the Healthcare Plans median (#8 of 18)

No single metric tells the full story. See the PGNY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Progyny Business Description

Address 1359 Broadway, New York, NY, USA, 10018
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
94GF Score

Get the complete analysis for PGNY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.88
Price
$28.66
GF Value